Integrated DNA Technologies

Executive Summary

Integrated DNA Technologies (IDT) is a premier provider of custom nucleic acid synthesis and genomic analysis solutions, serving research, diagnostics, and synthetic biology markets since 1987. With over 90% of standard orders shipped within 24 hours, IDT's core value proposition is high-quality, rapid-turnaround custom oligo synthesis, including products for PCR, qPCR, CRISPR gene editing, and next-generation sequencing (NGS). The company holds a strong competitive position due to its manufacturing scale, quality control, and broad portfolio of oligonucleotides, gene fragments, and reagents. IDT is well-positioned to benefit from growing demand for synthetic biology tools, CRISPR-based therapies, and NGS applications in clinical diagnostics. The company's continued investment in automation and capacity expansion supports its ability to meet increasing customer needs while maintaining rapid delivery. As a privately held firm, IDT focuses on operational excellence and customer loyalty, which drives repeat business and market share gains. The convergence of genomics, synthetic biology, and precision medicine creates significant tailwinds for IDT's product lines, particularly as researchers and biopharma companies accelerate drug discovery and development programs.

Upcoming Catalysts (preview)

• Q3 2026Launch of High-Throughput Gene Synthesis Platform80% success
• Q4 2026Partnership with Major Diagnostic Company for NGS Reagents60% success
• Q2 2026Expansion of CRISPR Oligo Manufacturing Capacity90% success